Skeletal Muscle Complications in Chronic Kidney Disease

Troutman, Ashley; Arroyo, Eliott; Lim, Kenneth; Moorthi, Ranjani N.; Avin, Keith G.

doi:10.1007/s11914-022-00751-w

Cited by 10 publications

(9 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is suggested that a high intake of protein might enhance glomerular filtration rate, sharply increasing the glomerular pressure and/or causing renal hypertrophy and predisposing to the development of renal damage and CKD [ 59 , 60 ]. In this context, the negative association found between lower-limb muscle power measures and BW-adjusted protein might be the result of long-term impairments of kidney function leading to muscle atrophy and dynapenia [ 61 ].…”

Section: Discussionmentioning

confidence: 99%

Lower-Limb Muscle Power Is Negatively Associated with Protein Intake in Older Adults: A Cross-Sectional Study

Coelho-Júnior

Azzolino

Calvani

et al. 2022

IJERPH

View full text Add to dashboard Cite

The present study examined the association between lower-limb muscle power and protein-related parameters in older adults. This study followed a cross-sectional design. Participants were community-dwelling older adults. Candidates were considered eligible if they were 60 years or older, lived independently, and possessed sufficient physical and cognitive abilities to perform all the measurements required by the protocol. The 5 times sit-to-stand (5STS) test was performed as fast as possible according to a standard protocol. Absolute, relative, and allometric muscle power measures were estimated using 5STS-based equations. Diet was assessed by 24-h dietary recall and diet composition was estimated using a nutritional software. One-hundred and ninety-seven older adults participated to the present study. After adjustment for covariates, absolute and allometric muscle power were negatively associated with body weight-adjusted protein intake. Our findings indicate that absolute and allometric muscle power estimated through a simple equation are negatively associated with body weight-adjusted protein intake in community-dwelling older adults.

show abstract

Section: Discussionmentioning

confidence: 99%

Lower-Limb Muscle Power Is Negatively Associated with Protein Intake in Older Adults: A Cross-Sectional Study

Coelho-Júnior

Azzolino

Calvani

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…In humans, atrophy can be detected by ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), which determine the cross-sectional area of total muscle tissue and the overall myofiber content. However, these imaging techniques cannot visualize individual cells, and they cannot detect atrophy in individual myofibers [14]. On a cellular level, atrophy is caused by a dysregulation of protein turnover where the balance is shifted from protein synthesis to degradation.…”

Section: Traditional Factorsmentioning

confidence: 99%

“…In CKD patients, exercise improves kidney parameters and the maximum rate of oxygen consumption [440,445]. However, to date, exercise interventions to improve muscle mass and function in CKD patients have demonstrated inconsistent responses, and the analyses of underlying mechanisms showed conflicting results [4,14,[446][447][448][449][450]. Some studies in non-dialysis and dialysis patients have reported beneficial effects of exercise on skeletal muscle, including increases in the crosssectional area of myofibers and muscle strength, reductions in oxidative stress, inflammation, and levels of myostatin and FGF23, as well as elevations in mitochondrial mass and function and serum sKL levels, while other studies have failed to do so [291,359,440,445,[451][452][453][454][455][456][457][458].…”

Section: Exercise As Therapy For Ckd-associated Sarcopeniamentioning

confidence: 99%

“…It has been reported that sarcopenia affects 5 to 65% of CKD patients [8][9][10][11][12][13]. This wide range in prevalence seems not only to be due to differences in disease stage, but also based on the heterogenous CKD patient population presenting with various comorbidities and undergoing different therapies, as well as the variability in the definition of sarcopenia, in the precise muscle tissue and myofiber type that is analyzed, and in the techniques used to assess muscle mass and function [4,14,15]. Nevertheless, sarcopenia and the resulting decline in physical performance and frailty are associated with CKD severity [11,[16][17][18][19][20][21][22][23][24], affecting more than 50% of dialysis patients [25], with higher incidence in men than in women [26].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Skeletal Muscle Injury in Chronic Kidney Disease—From Histologic Changes to Molecular Mechanisms and to Novel Therapies

Heitman,

Alexander,

Faul

2024

IJMS

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is associated with significant reductions in lean body mass and in the mass of various tissues, including skeletal muscle, which causes fatigue and contributes to high mortality rates. In CKD, the cellular protein turnover is imbalanced, with protein degradation outweighing protein synthesis, leading to a loss of protein and cell mass, which impairs tissue function. As CKD itself, skeletal muscle wasting, or sarcopenia, can have various origins and causes, and both CKD and sarcopenia share common risk factors, such as diabetes, obesity, and age. While these pathologies together with reduced physical performance and malnutrition contribute to muscle loss, they cannot explain all features of CKD-associated sarcopenia. Metabolic acidosis, systemic inflammation, insulin resistance and the accumulation of uremic toxins have been identified as additional factors that occur in CKD and that can contribute to sarcopenia. Here, we discuss the elevation of systemic phosphate levels, also called hyperphosphatemia, and the imbalance in the endocrine regulators of phosphate metabolism as another CKD-associated pathology that can directly and indirectly harm skeletal muscle tissue. To identify causes, affected cell types, and the mechanisms of sarcopenia and thereby novel targets for therapeutic interventions, it is important to first characterize the precise pathologic changes on molecular, cellular, and histologic levels, and to do so in CKD patients as well as in animal models of CKD, which we describe here in detail. We also discuss the currently known pathomechanisms and therapeutic approaches of CKD-associated sarcopenia, as well as the effects of hyperphosphatemia and the novel drug targets it could provide to protect skeletal muscle in CKD.

show abstract

“…Pediatricians celebrate a child’s first steps; geriatricians worry when an older adult walks more slowly. Chronic kidney disease (CKD) drives muscle loss, 1 and a previous study has shown that limited physical function predicts mortality in CKD. 2 Despite nearly one-fifth of people with CKD using an assistive device for ambulation, 2 the trajectory of how physical function changes with CKD progression, including the transition to dialysis, is not well understood.…”

mentioning

confidence: 99%